The efficacy of anti-MUC1 MAb C595 has been reported in oral squamous cell carcinomas (OSCCs), where MAb C595 induced complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to OSCC cells; this effect was strongly correlated with MUC1 expression [36]. The gene discussed is MUC1; the disease is oral cavity squamous cell carcinoma.